Myles D. Greenberg, MD, MBA
President & Chief Executive Officer
Dr. Myles Greenberg brings to InCarda more than 25 years of experience in growing life sciences firms as an entrepreneur, operating executive, board member, clinician and investor.
Prior to joining InCarda, Dr. Greenberg was CEO of Alucent Biomedical where he raised $75 million of institutional financing and brought a novel drug-device combination therapy from concept through product development and successful completion of clinical studies. He was also previously chief development officer at IntegraMed America (acquired by US Fertility).
Before becoming a full-time operating executive, Dr. Greenberg was a partner or principal at VC firms CHL Medical Partners, HealthInvest Equity Partners and Pappas Ventures. He was an early-stage investor and founding, active or lead board member in a number of biotechnology, medical device, and healthcare service companies such as Ambra Health (acquired by Intelerad Medical Systems), Angiomics (acquired by PDL BioPharma), Flowcardia (acquired by CR Bard), Liposcience (acquired by LabCorp), Millennium Pharmacy Systems (acquired by PharMerica), Oriel Therapeutics (acquired by Novartis), NuVasive (Nasdaq: NUVA, subsequently acquired by Globus), Syntonix Pharmaceuticals (acquired by Biogen Idec), CareWell Urgent Care (acquired by a PE firm), Vascular Pathways (acquired by CR Bard), and Vertos Medical (acquired by Stryker).
Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center / Harvard Medical School in Boston. He holds an MBA from Harvard Business School, MD from the Yale University School of Medicine and a BAS from the University of Pennsylvania School of Engineering and Applied Science. Dr. Greenberg is a Diplomate of the American Board of Emergency Medicine and currently holds an adjunct faculty appointment at the University of Utah School of Medicine.